News & Events

News

All categories

Earnings

Press Release

All years

2020

2019

2018

2017

2016

2015

2014

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma

January 25, 2016

Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

January 21, 2016

Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York City

January 20, 2016

Affimed Announces Addition of Dr. Andrew Evens to Scientific Advisory Board

January 14, 2016

Affimed to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference

January 12, 2016

Affimed Added to NASDAQ Biotech Index®

December 14, 2015

Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH

December 6, 2015

Affimed Presents Data Comparing T-cell- and NK-cell- engaging TandAbs AFM11 and AFM12 at ASH

December 6, 2015

Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development, Expansion of US Presence

December 2, 2015

Affimed to Present at the Oppenheimer 26th Annual Healthcare Conference –New York

December 1, 2015

Events

All

Scientific

Investors

29May

ASCO 2020 Annual Meeting

May 29 - June 2, 2020 (TBD)

25Aug

Innate Killer Summit 2020

August 25 - July 26, 2020 (San Diego, USA)
Presenter: Joachim Koch

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.